Antimalarial Drug Resistance: A Brief History of Its Spread in Indonesia

References

• Carter R, Mendis KN. Evolutionary and historical aspects of the burden of malaria. Clin Microbiol Rev. 2002;15(4):564–594. doi:10.1128/CMR.15.4.564-594.2002
   PubMed Web of Science ®Google Scholar
• Cox FEG. History of the discovery of the malaria parasites and their vectors. Parasit Vectors. 2010;3(1):5. doi:10.1186/1756-3305-3-5
   PubMedGoogle Scholar
• Ipa M Eliminasi malaria di Indonesia begitu sulit, mengapa? [Eliminating malaria in Indonesia is so difficult, why?]; 2018. Available from: https://theconversation.com/eliminasi-malaria-di-indonesia-begitu-sulit-mengapa-92754. Accessed January 4, 2023.
   Google Scholar
• World Health Organization. Evidence-informed action to eliminate malaria in Indonesia; 2022. Available from: https://www.who.int/about/accountability/results/who-results-report-2020-mtr/country-story/2021/indonesia. Accessed January 4, 2023.
   Google Scholar
• Elyazar IRF, Hay SI, Baird JK. Malaria distribution, prevalence, drug resistance and control in Indonesia. Adv Parasitol. 2011;74:41–175. doi:10.1016/B978-0-12-385897-9.00002-1
   PubMed Web of Science ®Google Scholar
• Ministry of Health Indonesia. Informasi Malaria Tahun 2022. [Malaria Information for 2022]. Available from: https://p2pm.kemkes.go.id/publikasi/infografis/informasi-malaria-tahun-2022. Accessed March 27, 2023
   Google Scholar
• Ebisawa I, Fukuyama T. Chloroquine resistance of Plasmodium falciparum in West Irian and East Kalimantan. Ann Trop Med Parasitol. 1975;69(3):275–282. doi:10.1080/00034983.1975.11687011
   PubMed Web of Science ®Google Scholar
• Tjitra E, Gunawan S, Laihad F, et al. Evaluation of antimalarial drugs in Indonesia, 1981–1995. Indones Bull Heal Res. 1997;25(1). doi:10.22435/bpk.v25i1Mar.242
   Google Scholar
• Kagoro FM, Barnes KI, Marsh K, et al. Mapping genetic markers of artemisinin resistance in Plasmodium falciparum malaria in Asia: a systematic review and spatiotemporal analysis. Lancet Microbe. 2022;3(3):e184–e192. doi:10.1016/S2666-5247(21)00249-4
   PubMedGoogle Scholar
• Wani WA, Jameel E, Baig U, Mumtazuddin S, Hun LT. Ferroquine and its derivatives: new generation of antimalarial agents. Eur J Med Chem. 2015;101:534–551. doi:10.1016/j.ejmech.2015.07.009
   PubMed Web of Science ®Google Scholar
• Sitohang V, Sariwati E, Fajariyani SB, et al. Malaria elimination in Indonesia: halfway there. Lancet Glob Heal. 2018;6(6):e604–e606. doi:10.1016/S2214-109X(18)30198-0
   PubMed Web of Science ®Google Scholar
• World Health Organization. “Zero malaria starts with me”: history of malaria elimination in Indonesia helps to shape a malaria-free future; 2020. Available from: https://www.who.int/indonesia/news/feature-stories/detail/zero-malaria-starts-with-me-history-of-malaria-elimination-in-indonesia-helps-to-shape-a-malaria-free-future. Accessed January 4, 2023.
   Google Scholar
• World Heal Organisation. Word Malaria Report 2021. Geneva: World Health Organization; 2021.
   Google Scholar
• Rahmasari FV, Asih PBS, Dewayanti FK, et al. Drug resistance of Plasmodium falciparum and Plasmodium vivax isolates in Indonesia. Malar J. 2022;21(1):1–32. doi:10.1186/s12936-022-04385-2
   PubMedGoogle Scholar
• Reyburn H. New WHO guidelines for the treatment of malaria. BMJ. 2010;340(7765):161–162. doi:10.1136/BMJ.C2637
   Google Scholar
• Kumar S, Bhardwaj TR, Prasad DN, Singh RK. Drug targets for resistant malaria: historic to future perspectives. Biomed Pharmacother. 2018;104:8–27. doi:10.1016/J.BIOPHA.2018.05.009
   PubMed Web of Science ®Google Scholar
• Shibeshi MA, Kifle ZD, Atnafie SA. Antimalarial Drug resistance and novel targets for antimalarial drug discovery. Infect Drug Resist. 2020;13:4047. doi:10.2147/IDR.S279433
   PubMed Web of Science ®Google Scholar
• Haldar K, Bhattacharjee S, Safeukui I. Drug resistance in Plasmodium. Nat Rev Microbiol. 2018;16(3):156. doi:10.1038/NRMICRO.2017.161
   PubMed Web of Science ®Google Scholar
• Sugiarto SR, Baird JK, Singh B, Elyazar I, Davis TME. The history and current epidemiology of malaria in Kalimantan, Indonesia. Malar J. 2022;21(1):327. doi:10.1186/s12936-022-04366-5
   PubMed Web of Science ®Google Scholar
• Cowell AN, Winzeler EA. The genomic architecture of antimalarial drug resistance. Brief Funct Genomics. 2019;18(5):314. doi:10.1093/BFGP/ELZ008
   PubMed Web of Science ®Google Scholar
• Wicht KJ, Mok S, Fidock DA. Molecular mechanisms of drug resistance in plasmodium falciparum malaria. Annu Rev Microbiol. 2020;74:431. doi:10.1146/ANNUREV-MICRO-020518-115546
   PubMed Web of Science ®Google Scholar
• Martin RE, Shafik SH, Richards SN. Mechanisms of resistance to the partner drugs of artemisinin in the malaria parasite. Curr Opin Pharmacol. 2018;42:71–80. doi:10.1016/j.coph.2018.07.010
   PubMed Web of Science ®Google Scholar
• Aliyu AW, Mustaffa KMF, Yew LC, Hou LJ. Chloroquine bioconjugates and hybrid compounds: past and recent developments in combatting chloroquine resistant malaria. Trop J Pharm Res. 2021;20(12):2663–2674. doi:10.4314/tjpr.v20i12.29
   Web of Science ®Google Scholar
• Cheema HS, Singh MP. Drug resistance in plasmodium, future malaria management strategies and importance of medicinal plants. J Ayurvedic Herb Med. 2022;8(2):107–112. doi:10.31254/jahm.2022.8209
   Google Scholar
• Kublin JG, Dzinjalamala FK, Kamwendo DD, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185(3):380–388. doi:10.1086/338566
   PubMed Web of Science ®Google Scholar
• Moss S, Mańko E, Krishna S, Campino S, Clark TG, Last A. How has mass drug administration with dihydroartemisinin-piperaquine impacted molecular markers of drug resistance? A systematic review. Malar J. 2022;21(1):1–23. doi:10.1186/s12936-022-04181-y
   PubMed Web of Science ®Google Scholar
• Asih PBS, Rozi IE, Dewayanti FK, et al. Efficacy and safety of dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Papua and Sumatra, Indonesia. Malar J. 2022;21(1):95. doi:10.1186/s12936-022-04101-0
   PubMed Web of Science ®Google Scholar
• Popovici J, Tebben K, Witkowski B, Serre D. Primaquine for Plasmodium vivax radical cure: what we do not know and why it matters. Int J Parasitol Drugs Drug Resist. 2021;15:36–42. doi:10.1016/j.ijpddr.2020.12.004
   PubMed Web of Science ®Google Scholar
• Camarda G, Jirawatcharadech P, Priestley RS, et al. Antimalarial activity of primaquine operates via a two-step biochemical relay. Nat Commun. 2019;10(1):3226. doi:10.1038/s41467-019-11239-0
   PubMedGoogle Scholar
• Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 Alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102(4):688–700. doi:10.1002/cpt.690
   PubMed Web of Science ®Google Scholar
• Bennett JW, Pybus BS, Yadava A, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013;369(14):1381–1382. doi:10.1056/NEJMc1301936
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang C-J, Chia WN, et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat Commun. 2015;6:10111. doi:10.1038/ncomms10111
   PubMed Web of Science ®Google Scholar
• Ismail HM, Barton V, Phanchana M, et al. Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7. Proc Natl Acad Sci U S A. 2016;113(8):2080–2085. doi:10.1073/pnas.1600459113
   PubMed Web of Science ®Google Scholar
• Lacy MD, Maguire JD, Barcus MJ, et al. Atovaquone/proguanil therapy for plasmodium falciparum and plasmodium vivax malaria in Indonesians who lack clinical immunity. Clin Infect Dis. 2002;35(9):e92–e95. doi:10.1086/343750
   PubMed Web of Science ®Google Scholar
• Ippolito MM, Moser KA, Kabuya J-B-B, Cunningham C, Juliano JJ. Antimalarial drug resistance and implications for the WHO global technical strategy. Curr Epidemiol Reports. 2021;8(2):46–62. doi:10.1007/s40471-021-00266-5
   PubMedGoogle Scholar
• Bazie VB, Ouattara AK, Sagna T, et al. Resistance of plasmodium falciparum to sulfadoxine-pyrimethamine (dhfr and dhps) and artemisinin and its derivatives (K13): a major challenge for malaria elimination in West Africa. J Biosci Med. 2020;8(2):82–95. doi:10.4236/jbm.2020.82007
   Google Scholar
• Heinberg A, Kirkman L. The molecular basis of antifolate resistance in Plasmodium falciparum: looking beyond point mutations. Ann N Y Acad Sci. 2015;1342(1):10–18. doi:10.1111/nyas.12662
   PubMed Web of Science ®Google Scholar
• Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat Med. 2017;23(8):917. doi:10.1038/NM.4381
   PubMed Web of Science ®Google Scholar
• Sanchez CP, Liu CH, Mayer S, et al. A HECT ubiquitin-protein ligase as a novel candidate gene for altered quinine and quinidine responses in plasmodium falciparum. PLOS Genet. 2014;10(5):e1004382. doi:10.1371/JOURNAL.PGEN.1004382
   PubMed Web of Science ®Google Scholar
• Ferdig MT, Cooper RA, Mu J, et al. Dissecting the loci of low-level quinine resistance in malaria parasites. Mol Microbiol. 2004;52(4):985–997. doi:10.1111/J.1365-2958.2004.04035.X
   PubMed Web of Science ®Google Scholar
• Cooper RA, Lane KD, Deng B, et al. Mutations in transmembrane domains 1, 4 and 9 of the Plasmodium falciparum chloroquine resistance transporter alter susceptibility to chloroquine, quinine and quinidine. Mol Microbiol. 2007;63(1):270–282. doi:10.1111/J.1365-2958.2006.05511.X
   PubMed Web of Science ®Google Scholar
• Sidhu ABS, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA. Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis. 2006;194(4):528. doi:10.1086/507115
   PubMed Web of Science ®Google Scholar
• Cowman AF, Galatis D, Thompson JK. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci U S A. 1994;91(3):1143. doi:10.1073/PNAS.91.3.1143
   PubMed Web of Science ®Google Scholar
• Rosenthal PJ. Azithromycin for Malaria? Am J Trop Med Hyg. 2016;95(1):2. doi:10.4269/AJTMH.16-0332
   PubMed Web of Science ®Google Scholar
• Lell B, Kremsner PG. Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob Agents Chemother. 2002;46(8):2315. doi:10.1128/AAC.46.8.2315-2320.2002
   PubMed Web of Science ®Google Scholar
• Gaillard T, Madamet M, Pradines B. Tetracyclines in malaria. Malar J. 2015;14(1):445. doi:10.1186/S12936-015-0980-0
   PubMedGoogle Scholar
• Newton PN, Chaulet JF, Brockman A, et al. Pharmacokinetics of oral doxycycline during combination treatment of severe falciparum malaria. Antimicrob Agents Chemother. 2005;49(4):1622–1625. doi:10.1128/AAC.49.4.1622-1625.2005
   PubMed Web of Science ®Google Scholar
• Sheridan CM, Garcia VE, Ahyong V, DeRisi JL. The Plasmodium falciparum cytoplasmic translation apparatus: a promising therapeutic target not yet exploited by clinically approved anti-malarials. Malar J. 2018;17(1):1–13. doi:10.1186/S12936-018-2616-7
   PubMedGoogle Scholar
• Dahl EL, Rosenthal PJ. multiple antibiotics exert delayed effects against the plasmodium falciparum apicoplast. Antimicrob Agents Chemother. 2007;51(10):3485. doi:10.1128/AAC.00527-07
   PubMed Web of Science ®Google Scholar
• Dahl EL, Rosenthal PJ. Apicoplast translation, transcription and genome replication: targets for antimalarial antibiotics. Trends Parasitol. 2008;24(6):279–284. doi:10.1016/j.pt.2008.03.007
   PubMed Web of Science ®Google Scholar
• Dharia NV, Plouffe D, Bopp SER, et al. Genome scanning of Amazonian Plasmodium falciparum shows subtelomeric instability and clindamycin-resistant parasites. Genome Res. 2010;20(11):1534. doi:10.1101/GR.105163.110
   PubMed Web of Science ®Google Scholar
• Eckstein-Ludwig U, Webb RJ, Van Goethem IDA, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nat. 2003;424(6951):957–961. doi:10.1038/nature01813
   Google Scholar
• Tilley L, Straimer J, Gnädig NF, Ralph SA, Fidock DA. Artemisinin action and resistance in Plasmodium falciparum. Trends Parasitol. 2016;32(9):682. doi:10.1016/J.PT.2016.05.010
   PubMed Web of Science ®Google Scholar
• Auparakkitanon S, Wilairat P, Wilairat P. Will the in situ activator(s) of artemisinin please stand up? Mol Biochem Parasitol. 2022;248:2021–2023. doi:10.1016/j.molbiopara.2022.111461
   Web of Science ®Google Scholar
• Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505(7481):50–55. doi:10.1038/NATURE12876
   PubMed Web of Science ®Google Scholar
• Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371(5):411–423. doi:10.1056/NEJMOA1314981
   PubMed Web of Science ®Google Scholar
• Straimer J, Gnädig NF, Witkowski B, et al. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015;347(6220):428. doi:10.1126/SCIENCE.1260867
   PubMed Web of Science ®Google Scholar
• Dogovski C, Xie SC, Burgio G, et al. Targeting the cell stress response of plasmodium falciparum to overcome artemisinin resistance. PLOS Biol. 2015;13(4):e1002132. doi:10.1371/JOURNAL.PBIO.1002132
   PubMed Web of Science ®Google Scholar
• Mbengue A, Bhattacharjee S, Pandharkar T, et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature. 2015;520(7549):683. doi:10.1038/NATURE14412
   PubMed Web of Science ®Google Scholar
• Behrens HM, Schmidt S, Peigney D, May J, Maïga-Ascofaré O, Spielmann T. Moderate ART resistance mutations with low fitness cost in malaria parasites from Africa. bioRxiv. 2022;2022:5.
   Google Scholar
• Manirakiza G, Kassaza K, Taremwa IM, Bazira J, Byarugaba F. Molecular identification and anti-malarial drug resistance profile of Plasmodium falciparum from patients attending Kisoro Hospital, southwestern Uganda. Malar J. 2022;21(1):1–10. doi:10.1186/s12936-021-04023-3
   PubMed Web of Science ®Google Scholar
• Nsanzabana C, Djalle D, Guérin PJ, Ménard D, González IJ. Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape. Malar J. 2018;17(1):1–16. doi:10.1186/s12936-018-2185-9
   PubMedGoogle Scholar
• Slater L, Betson M, Ashraf S, Sargison N, Chaudhry U. Current methods for the detection of antimalarial drug resistance in Plasmodium parasites infecting humans. Acta Trop. 2021;216:105828. doi:10.1016/j.actatropica.2021.105828
   PubMed Web of Science ®Google Scholar
• World Heal Organisation. Methods for Surveillance of Antimalarial Drug Efficacy. World Heal Organisation; 2009:90.
   Google Scholar
• World Heal Organisation. Strategy to Respond to Antimalarial Drug Resistance in Africa; 2022.
   Google Scholar
• Bloland PB. WHO/CDS/CSR/DRS/2001.4 drug resistance in malaria drug resistance in malaria; 2001. Available from: http://www.who.int/emc. Accessed January 9, 2022.
   Google Scholar
• Lê HG, Naw H, Kang JM, et al. Molecular profiles of multiple antimalarial drug resistance markers in plasmodium falciparum and plasmodium vivax in the Mandalay region, Myanmar. Microorganisms. 2022;10:10. doi:10.3390/microorganisms10102021
   Web of Science ®Google Scholar
• Shaukat A, Ali Q, Connelley T, et al. Selective sweep and phylogenetic models for the emergence and spread of pyrimethamine resistance mutations in Plasmodium vivax. Infect Genet Evol. 2019;68:221–230. doi:10.1016/j.meegid.2018.12.032
   PubMed Web of Science ®Google Scholar
• Haanshuus CG, Mørch K, Blomberg B, et al. Assessment of malaria real-time PCR methods and application with focus on lowlevel parasitaemia. PLoS One. 2019;14(7):1–15. doi:10.1371/journal.pone.0218982
   Google Scholar
• Rumans LW, Dennis DT, Atmosoedjono S. Fansidar resistant falciparum malaria in Indonesia. Lancet. 1979;2(8142):580–581. doi:10.1016/S0140-6736(79)91633-7
   PubMed Web of Science ®Google Scholar
• Ratcliff A, Siswantoro H, Kenangalem E, et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg. 2007;101(4):351–359. doi:10.1016/J.TRSTMH.2006.06.008
   PubMed Web of Science ®Google Scholar
• Asih PBS, Syafruddin D, Leake J, et al. Phenotyping clinical resistance to chloroquine in Plasmodium vivax in northeastern Papua, Indonesia. Int J Parasitol Drugs Drug Resist. 2011;1(1):28–32. doi:10.1016/j.ijpddr.2011.08.001
   PubMed Web of Science ®Google Scholar
• Fitriah F, Sulistyawati S, Riyanto S, et al. Polymorphism of Plasmodium Falciparum Dihydrofolate Reductase and Dihydropteroate Synthase Genes among Pregnant Women with Falciparum Malaria in Banjar District, South Kalimantan Province, Indonesia. J Trop Life Sci. 2012;3:92–98.
   Google Scholar
• Reteng P, Vrisca V, Sukarno I, et al. Genetic polymorphisms in Plasmodium falciparum chloroquine resistance genes, pfcrt and pfmdr1, in North Sulawesi, Indonesia. BMC Res Notes. 2017;10(1):1–8. doi:10.1186/s13104-017-2468-1
   PubMedGoogle Scholar
• Packard RM. The origins of antimalarial-drug resistance. N Engl J Med. 2014;371(5):397–399. doi:10.1056/NEJMP1403340/SUPPL_FILE/NEJMP1403340_DISCLOSURES.PDF
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Malaria - Chapter 4 - CDC Yellow Book 2020: Health Information for International Travel. Oxford University Press; 2019. Available from: https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/malaria. Accessed March 26, 2023.
   Google Scholar
• Lederman ER, Sutanto I, Wibudi A, et al. Imported Malaria in Jakarta, Indonesia: passive Surveillance of Returned Travelers and Military Members Postdeployment. J Travel Med. 2006;13(3):153–160. doi:10.1111/j.1708-8305.2006.00034.x
   PubMed Web of Science ®Google Scholar
• Ebisawa I, Fukuyama T, Kawamura Y. Additional foci of chloroquine-resistant falciparum malaria in East Kalimantan and West Irian, Indonesia. Trop Geogr Med. 1976;28:349–354.
   PubMedGoogle Scholar
• Verdrager J. Effect of single dose of minocycline on a chloroquine resistant falciparum infection from balikpapan, kalimantan. Bul Penelit Kesehat. 1975;3(2):63798.
   Google Scholar
• Tjitra E, Marwoto HA, Renny M, Ompusunggu S, Tuti S. Penelitian Obat Anti Malaria. [Anti-Malaria Drug Research]. Bul Penelit Kesehat. 1991;19(4Des). doi:10.22435/BPK.V19I4
   Google Scholar
• Pribadi W. In vitro sensitivity of Plasmodium falciparum to chloroquine and other antimalarials in East Timor and east Kalimantan, Indonesia. Southeast Asian J Trop Med Public Heal. 1992;23:143–148.
   PubMedGoogle Scholar
• Baird JK, Basri H, Subianto B, et al. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis. 1995;171(6):1678–1682. doi:10.1093/INFDIS/171.6.1678
   PubMed Web of Science ®Google Scholar
• Baird JK, Wiady I, Fryauff DJ, et al. In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. Am J Trop Med Hyg. 1997;56(6):627–631. doi:10.4269/AJTMH.1997.56.627
   PubMed Web of Science ®Google Scholar
• Sumawinata IW, Bernadeta B. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua - PubMed. Am J Trop Med Hyg. 2003;68(4):416–420.
   PubMed Web of Science ®Google Scholar
• Fryauff DJ, Soekartono TS. Survey of resistance in vivo to chloroquine of Plasmodium falciparum and P. vivax in North Sulawesi, Indonesia. Trans R Soc Trop Med Hyg. 1998;92(1):82–83. doi:10.1016/s0035-9203(98)90966-x
   PubMed Web of Science ®Google Scholar
• Sutanto I, Suprijanto S, Nurhayati MP, Baird JK. Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia. Am J Trop Med Hyg. 2009;81(2):338–342.
   PubMed Web of Science ®Google Scholar
• Sutanto I, Endawati D, Ling LH, Laihad F, Setiabudy R, Baird JK. Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia. Malar J. 2010;9(1):11–15. doi:10.1186/1475-2875-9-52
   PubMedGoogle Scholar
• Suwanarusk R, Russell B, Chavchich M, et al. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS One. 2007;2(10):e1089. doi:10.1371/journal.pone.0001089
   PubMed Web of Science ®Google Scholar
• Siswantoro H, Ratcliff A, Kenangalem E, et al. Efficacy of existing antimalarial drugs for uncomplicated malaria in Timika, Papua, Indonesia. Med J Indones. 2006;15(4):251–258. doi:10.13181/mji.v15i4.243
   Google Scholar
• Asih PB, Rogers WO, Susanti AI, et al. Seasonal distribution of anti-malarial drug resistance alleles on the island of Sumba, Indonesia. Malar J. 2009;8(1):1–7. doi:10.1186/1475-2875-8-222
   PubMedGoogle Scholar
• Salwati E, Herman R, Handayani S, Tjitra E, Deteksi P. Vivax Single Nucleotide Polymorphism (SNP) Y976F dari Sampel Monitoring Pengobatan Dihidroartemisinin-Piperakuin di Kalimantan dan Sulawesi. [Detection of P.vivax Single Nucleotide Polymorphism (SNP) Y976F from Monitoring Samples of Dihydroartemi. Media Penelit Dan Pengemb Kesehat. 2012;22. doi:10.22435/MPK.V22I3
   Google Scholar
• Saleh I, Handayani D, Anwar C. Polymorphisms in the pfcrt and pfmdr1 genes in Plasmodium falciparum isolates from South Sumatera, Indonesia. Med J Indones. 2014;23(1):3–8. doi:10.13181/MJI.V23I1.679
   Google Scholar
• Lubis IND, Wijaya H, Lubis M, Lubi CP, Beshi KB, Sutherlan CJ. Plasmodium falciparum Isolates Carrying pfk13 Polymorphisms Harbor the SVMNT Allele of pfcrt in Northwestern Indonesia. Antimicrob Agents Chemother. 2020;64:8. doi:10.1128/AAC.02539-19
   Web of Science ®Google Scholar
• Pickard AL, Wongsrichanalai C, Purfield A, et al. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother. 2003;47(8):2418–2423. doi:10.1128/AAC.47.8.2418-2423.2003
   PubMed Web of Science ®Google Scholar
• Ross LS, Dhingra SK, Mok S, et al. Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine. Nat Commun. 2018;9(1):25–28. doi:10.1038/s41467-018-05652-0
   PubMedGoogle Scholar
• Calçada C, Silva M, Baptista V, et al. Expansion of a Specific Plasmodium falciparum PfMDR1 Haplotype in Southeast Asia with Increased Substrate Transport. MBio. 2020;11:6. doi:10.1128/mBio.02093-20
   Web of Science ®Google Scholar
• Nagesha HS. Mutations in the pfmdr1, dhfr and dhps genes of Plasmodium falciparum are associated with in-vivo drug resistance in West Papua, Indonesia. Trans R Soc Trop Med Hyg. 2001;95(1):43–49. doi:10.1016/s0035-9203(01)90329-3
   PubMed Web of Science ®Google Scholar
• Hastings MD, Porter KM, Maguire JD, et al. Dihydrofolate reductase mutations in plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. J Infect Dis. 2004;189(4):744–750. doi:10.1086/381397
   PubMed Web of Science ®Google Scholar
• Syafruddin D, Asih PBS, Casey GJ, et al. Molecular epidemiology of Plasmodium falciparum resistance to antimalarial drugs in Indonesia. Am J Trop Med Hyg. 2005;72(2):174–181. doi:10.4269/ajtmh.2005.72.174
   PubMed Web of Science ®Google Scholar
• Maguire JD, Lacy MD, Sururi H, et al. Chloroquine or sulfadoxine-pyrimethamine for the treatment of uncomplicated, Plasmodium falciparum malaria during an epidemic in Central Java, Indonesia. Ann Trop Med Parasitol. 2002;96(7):655–668. doi:10.1179/000349802125002310
   PubMed Web of Science ®Google Scholar
• Fryauff DJ, Leksana B, Masbar S, et al. The drug sensitivity and transmission dynamics of human malaria on Nias Island, North Sumatra, Indonesia. Ann Trop Med Parasitol. 2002;96(5):447–462. doi:10.1179/000349802125001249
   PubMed Web of Science ®Google Scholar
• Basuki S, Fitriah RS, Budiono DYP, Uemura H. Two novel mutations of pfdhps K540T and I588F, affecting sulphadoxine-pyrimethamine-resistant response in uncomplicated falciparum malaria at Banjar district, South Kalimantan Province, Indonesia. Malar J. 2014;13(1):135. doi:10.1186/1475-2875-13-135
   PubMedGoogle Scholar
• Asih PBS, Marantina SS, Nababan R, et al. Distribution of Plasmodium vivax pvdhfr and pvdhps alleles and their association with sulfadoxine–pyrimethamine treatment outcomes in Indonesia. Malar J. 2015;14(1):365. doi:10.1186/s12936-015-0903-0
   PubMedGoogle Scholar
• Jiang T, Cheng W, Yao Y, Tan H, Wu K, Li J. Molecular surveillance of anti-malarial resistance Pfdhfr and Pfdhps polymorphisms in African and Southeast Asia Plasmodium falciparum imported parasites to Wuhan, China. Malar J. 2020;19(1):434. doi:10.1186/s12936-020-03509-w
   PubMed Web of Science ®Google Scholar
• Kaingona-Daniel EPS, Gomes LR, Gama BE, et al. Low-grade sulfadoxine-pyrimethamine resistance in Plasmodium falciparum parasites from Lubango, Angola. Malar J. 2016;15:309. doi:10.1186/s12936-016-1358-7
   PubMed Web of Science ®Google Scholar
• Asih PBS, Dewi RM, Tuti S, et al. Efficacy of Artemisinin-Based Combination Therapy for Treatment of Persons with Uncomplicated Plasmodium falciparum Malaria in West Sumba District, East Nusa Tenggara Province, Indonesia, and Genotypic Profiles of the Parasite. Am J Trop Med Hyg. 2009;80(6):914–918. doi:10.4269/AJTMH.2009.80.914
   PubMed Web of Science ®Google Scholar
• Ghiffari A, Rahman R, Anwar C. No antimalarial resistance of Plasmodium falciparum varian West Indonesia using molecular markers screening. J Phys Conf Ser. 2019;1282:1. doi:10.1088/1742-6596/1282/1/012077
   Google Scholar
• Rachmad B. Isolasi dan Identifikasi Mutasi Gen PfK13 (PF3D7_1343700) sebagai penanda resistensi artemisinin pada isolat plasmodium falciparum Asal lampung. [Isolation and Identification of PfK13 gene mutation (PF3D7_1343700) as a marker of artemisinin resistance in P. Pros dalam rangka Rakernas. 2019;2019:1.
   Google Scholar
• Amato R, Pearson RD, Almagro-Garcia J, et al. Origins of the current outbreak of multidrug-resistant malaria in Southeast Asia: a retrospective genetic study. Lancet Infect Dis. 2018;18(3):337–345. doi:10.1016/S1473-3099(18)30068-9
   PubMed Web of Science ®Google Scholar
• Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004;364(9432):438–447. doi:10.1016/S0140-6736(04)16767-6
   PubMed Web of Science ®Google Scholar
• Sidhu AB, Valderramos SG, Fidock DA. Pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol. 2005;57(4):913–26. doi:10.1111/j.1365-2958.2005.04729.x
   PubMed Web of Science ®Google Scholar
• Sisowath C, Strömberg J, Mårtensson A, et al. In Vivo Selection of Plasmodium falciparum pfmdr1 86N Coding Alleles by Artemether‐Lumefantrine (Coartem). J Infect Dis. 2005;191(6):1014–1017. doi:10.1086/427997
   PubMed Web of Science ®Google Scholar
• Sisowath C, Ferreira PE, Bustamante LY, et al. The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Tropical Medicine & International Health. 2007;12(6):736–742. doi:10.1111/j.1365-3156.2007.01843.x
   PubMed Web of Science ®Google Scholar
• Lu K, Derbyshire ER. Tafenoquine: A Step toward Malaria Elimination. Biochemistry. 2020;59(8):911–920. doi:10.1021/acs.biochem.9b01105
   PubMed Web of Science ®Google Scholar